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Abstract
Background: Shikonin, a phytochemical purified from Lithospermum erythrorhizon, has been shown to confer
diverse pharmacological activities, including accelerating granuloma formation, wound healing, anti-inflammation
and others, and is explored for immune-modifier activities for vaccination in this study. Transdermal gene-based
vaccine is an attractive approach for delivery of DNA transgenes encoding specific tumor antigens to host skin
tissues. Skin dendritic cells (DCs), a potent antigen-presenting cell type, is known to play a critical role in
transmitting and orchestrating tumor antigen-specific immunities against cancers. The present study hence
employs these various components for experimentation.
Method: The mRNA and protein expression of RANTES were detected by RT-PCR and ELISA, respectively. The
regional expression of RANTES and tissue damage in test skin were evaluated via immunohistochemistry assay.
Fluorescein isothiocyanate sensitization assay was performed to trace the trafficking of DCs from the skin
vaccination site to draining lymph nodes. Adjuvantic effect of shikonin on gene gun-delivered human gp100
(hgp100) DNA cancer vaccine was studied in a human gp100-transfected B16 (B16/hgp100) tumor model.
Results: Among various phytochemicals tested, shikonin induced the highest level of expression of RANTES in
normal skin tissues. In comparison, mouse RANTES cDNA gene transfection induced a higher level of mRANTES
expression for a longer period, but caused more extensive skin damage. Topical application of shikonin onto the
immunization site before gene gun-mediated vaccination augmented the population of skin DCs migrating into
the draining lymph nodes. A hgp100 cDNA gene vaccination regimen with shikonin pretreatment as an adjuvant
in a B16/hgp100 tumor model increased cytotoxic T lymphocyte activities in splenocytes and lymph node cells on
target tumor cells.
Conclusion: Together, our findings suggest that shikonin can effectively enhance anti-tumor potency of a gene-
based cancer vaccine via the induction of RANTES expression at the skin immunization site.
Background
Shikonin, a phytochemical from the traditional herbal
medicine Lithospermum erythrorhizon, has been shown
to possess diverse pharmacological properties, including
anti-oxidant [1], wound healing [2-4], anti-inflammatory
[5] and anti-tumor properties [6,7]. Anti-inflammatory
activities of shikonin can be mediated by suppression of
TNF-a promoter activity [8] or by regulation of TNF-a
pre-mRNA splicing [9]. Wound-healing activity of shiko-
nin resulted in proliferation of fibroblasts and collagen
fiber levels in granuloma tissues, and an increase in the
CD11b
+ cell population in granulation tissues [3,4].
These findings suggest that shikonin may confer cellular
activities that can induce specific chemokines and subse-
quent chemotactic activities in specific immune-respon-
sive cell types.
Transdermal or dermal delivery as a strategy of adminis-
tration for specific vaccines, therapeutic agents and experi-
mental medicines, is an attractive approach due to the
presence and unique features of key immunocompetent
cells in skin tissues, such as keratinocytes and dendritic
cells (DCs), which include both dermal and epidermal
DCs. DCs are potent professional antigen presenting cells
that can act as sentinels that constantly monitor the
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any medium, provided the original work is properly cited.surrounding milieu. They can be activated by a variety of
cellular or microenvironmental signals produced by invad-
ing pathogens or neighboring cells [10,11]. Activated skin
DCs can migrate from the epidermis or dermis to the
draining lymph nodes where antigen presentation takes
place [12]. On the basis of the specific characteristics of
DCs, advanced vaccine strategies have been designed to
target antigens onto DCs, promoting cross-priming and
improving peptide-binding to both MHC class I and class
II molecules [13]. Evidence has accumulated showing that
DCs can play a critical role in eliciting immunity from
DNA-based vaccination [14,15].
Chemotactic-tumor associated antigen vaccines have
been reported to target specific antigens to special
immune cell types, and thereby elicit improved immune
responses [16]. Previously it was suggested that the major-
ity of cells transfected by gene gun-mediated vaccination
(in skin) were non-antigen presenting cells [17]; however,
a relatively small but significant number of transgene-
expressing DCs were detected in the draining lymph
nodes [18]. Timares and his colleagues [17] also suggested
that directly-transfected DCs can incite immune response
in a more efficient way than indirectly-transfected DCs. As
compared to conventional vaccines, the success of skin
vaccination via gene gun delivery has been challenged by
its capacity to elicit only limited immunity [19]. In a recent
study, we reported that co-vaccination with a chemokine,
mouse RANTES (mRANTES) and a tumor-specific anti-
gen gene, human gp100 (hgp100) within a specific time
frame can induce a strong cell-mediated immunity against
targeted B16/hgp100-tumor cells [20]. Gene gun-mediated
bombardment with RANTES cDNA transgene signifi-
cantly increased CD11c
+,N K 1 . 1
+,C D 4
+ and CD8
+
immune cells in test mouse skin. RANTES, which is regu-
lated upon activation of normal T-cell expression and
secretion, is a versatile chemokine which can not only
recruit leukocytes into the inflamed tissue sites, but can
also act as a powerful leukocyte activator [21]. High level
induction of RANTES in keratinocytes has been reported
for cutaneous wound-repairing [22].
Here, we evaluated the effects of topical application of
shikonin to skin to aid trafficking of skin DCs and thus
augment the effect of a DNA-based cancer vaccine. We
investigated the effects of shikonin on the induction of
RANTES in treated skin tissues that subsequently served
as the immunization site for hgp100 gene-based cancer
vaccines. Our findings suggest that shikonin can effectively
enhance the efficacy of the tumor associated antigen-
hgp100 DNA vaccine, and its effect is likely mediated via
the induction of mRANTES and an increase in the popu-
lation of skin DCs at the vaccinated site draining into
lymph nodes. Possible implication and application of phy-
tochemical shikonin for generic and topical use as an adju-
vant in skin-based vaccinations are discussed.
Methods
Animals
Male C57BL/6Jnarl mice (6-8-weeks old) were purchased
from the National Laboratory Animal Breeding and
Research Center, Taipei, Taiwan. All mice were main-
tained in a laminar airflow cabinet in a room kept at 24 ±
2°C and 40-70% humidity with a 12 h light/dark cycle
under specific pathogen-free conditions. All facilities were
approved by the Academia Sinica Institutional Animal
Care and Utilization Committee, and all animal experi-
ments were conducted under the institutional guidelines
established for the Animal Core Facility at Academia
Sinica, Taipei.
Compounds
Shikonin was purchased from Tokyo Chemical Industry.
Gallic acid, ferulic acid, curcumin, caffeic acid and epi-
gallocatechin-3-gallate, phorbol ester 12-O-tetradeca-
noylphorbol-13-acetate were purchased from Sigma.
Tumor cells and transfectants
The B16F10 melanoma cell line, syngeneic in C57BL/6
mice, was purchased from American Type Culture Collec-
tion (ATCC). Human gp100-transfected B16 cell line were
obtained by stably transfecting B16 cells using the Powder-
Ject gene delivery system (PowderJect Vaccines) as
described previously [18,23]. B16/hgp100 cells were main-
tained in DMEM supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, and 100 μg/ml streptomycin
and penicillin.
Construction of cDNA expression vector and transgene
Human gp100 (hgp100) expression plasmid pWRG1644
was a kind gift from Dr Nicholas Restifo, National Cancer
Institute, (Bethesda, MD USA). pWRG1644 plasmid with-
out containing the coding sequence of hgp100 was used as
a control [24]. The pORF9-mRANTES mammalian expres-
sion vector was purchased from Invivogen (San Diego, CA,
USA).
Primer design and reverse transcriptase-PCR condition
Total RNA was extracted as per the manufacturer’s
instructions of the TRIzol reagent (Invitrogen). RT-PCR
reactions were conducted with the AccessQuick RT-PCR
system (Promega, Madison, WI), according to the manu-
facturer’s instructions, at cycle numbers that yielded pro-
ducts within the linear range as determined for each
specific pair of primers. Specific primer pairs for mouse
RANTES were 5’-ATATGGCTCGGACACCACTC and
5’-CCTTCGAGTGACAAACACGA.
Fluorescein isothiocyanate (FITC) sensitization assay
The assay method was modified from a previous study
[25]. FITC was dissolved in acetone/dibutylphthalate
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skin with 50 μl of 1% FITC solution. After 30 mins, shi-
konin (0, 50 or 100 μg/3.8 cm
2/site) or transgenic bom-
bardments were applied onto the test site. After FITC
painting for 24 hours, axillary, brachial and inguinal
lymph nodes were obtained, single-cell suspensions were
prepared[26], purified by anti-CD11c microbeads, and
then stained with PE-anti-MHC class II antibody. Flow
cytometry analysis by test cells was performed on a
FACScan.
Mouse models of skin inflammation
Protocols for creating skin inflammation in mice were
approved by the Institute Ethical Committee and
IACUC. For skin inflammation test, female C57BL/
6JNarl mice received a topical application on ~3.8 cm
2
area/site of the shaved abdomen with 10 nmol TPA. In
selected groups, 50 μl of the vehicle control or solutions
of test shikonin concentration was applied on test skin
30 min before challenge. Total RNA was extracted from
test skin tissues after 24 hours; chemokine expression
w a sa n a l y z e di ns u b s e q u e n tt i m ep o i n t sb yR T - P C R .I n
each experimental group, some of the mice were sacri-
ficed and the test skin samples were excised for snap
frozen for immunohistochemistry or histological
analysis.
Immunohistochemical and histological analysis
Skin tissue samples were collected and fixed in 10% PBS
buffered formalin and embedded in paraffin wax. Speci-
mens were cut into 5 μm-thick sections and mounted
on slides for the immunohistochemistry by a standard
indirect streptavidin-biotin immunoperoxidase staining
method. Specimens were treated with primary rat anti-
mouse mRANTES, and subsequent secondary biotin-
conjugated anti-rat IgG and tertiary peroxidase-conjugated
streptavidin (Serotec) [6,27]. Primary antibodies were pur-
chased from PharMingen (San Diego, CA, USA) or Sero-
tec. Apoptotic cells were detected with an in situ Cell
Death Kit (Roche Diagnostics). All test skin tissue sections
were counterstained with hematoxylin.
The subcutaneous B16/hgp100 tumor model and
cytotoxic T lymphocytes (CTL) assay
B16/hgp100 tumor cells were injected subcutaneously (1 ×
10
5 cells/100 μl/mouse) into the right flank of mice. On
day 7 post-tumor cell inoculation, test mice were vacci-
nated with hgp100 cDNA vector (3 μg each/mice).
mRANTES cDNA vector (3 μge a c h / m i c e )o rs h i k o n i n
(100 μg/site/mice) was transfected or topically applied to
equal area of abdominal skin, 24 hours before the
hgp100 cDNA vaccination. One primer and two boosters
were administered on day 0, 7 and 14. One week after the
last booster, splenocytes and lymph node cells were har-
vested from immunized mice and assayed for CTL activity
assayed according to the manufacturer’s protocol (DEL-
FIA, Perkin Elmer, MA, USA). The percentage of specific
lysis was calculated as (experimental release (counts)-
spontaneous release (counts))/(maximum release (counts)
- spontaneous release (counts)) × 100.
Statistical analysis
ANOVA or the T-test statistical method was employed
to analyze the data from different groups or treatments
of test herbs or phytochemicals.
Results
Effect of various phytochemicals on induction of RANTES
in mouse skin tissues
Six anti-inflammatory phytochemicals, gallic acid (GA),
ferulic acid (FA), curcumin (CM), caffeic acid (CA), epi-
gallocatechin gallate (EGCG), and shikonin (SK) were
selected to evaluate specific phytochemicals that may
regulate or modify the expression of mRANTES in skin
tissues. The phorbol ester, 12-O-tetradecanoylphorbol-
13-acetate (TPA), a well-known inflammation-inducing
agent, was used as a positive control for induction of
mRANTES. A clinically used therapeutic anti-inflamma-
tory drug, hydrocortisone (H), was used as a negative
control. H treatment did not affect the expression of
mRANTES in mouse skin samples (Figure 1). In compar-
ison, when equal concentrations (each at 0.7 mmole/skin
site/3.8 cm
2/mouse) of the six test phytochemicals were
applied topically to mouse skin, two phytochemicals
induced expression of mRANTES, c.a., SK and CM. Shi-
konin induced the highest level of expression of
mRANTES protein; close to 3-fold higher than that of
the vehicle control. CM also induced mRANTES expres-
sion, but to a lesser level than shikonin. In contrast, no
significant inductive effect was detected in GA, FA, CA
or EGCG-treated skin tissues.
Shikonin differentially affects expression of mRANTES and
MIP-1b mRNAs in normal and inflamed skin tissues
After 24 hours of topical treatment of normal skin with
two different doses of shikonin, mRNA expression of
mRANTES and MIP-1b was assayed. At a dose of 100
μg/site/mouse, shikonin was able to effectively induce
mRNA expression of mRANTES and mMIP-1b with
approximately 5- to 7-fold and 3- to 4-fold increases,
respectively, in comparison to non-treated skin tissue
(Figure 2a). These two chemokines have been reported to
promote the recruitment of leukocytes which can in turn
facilitate the tissue repair process [28,29]. We then
assessed the expression pattern of mRANTES mRNA in
shikonin-treated skin tissues in a time-course experiment
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mRANTES mRNA expression was detectable at 4 hours
after treatment with shikonin (100 μg/site/mouse); and
maximum level of expression was reached between 12
and 18 hours post-treatment (Figure 2b). Interestingly,
however, in skin tissue inflamed by TPA, mRANTES and
mMIP-1b were markedly downregulated by shikonin
(Figure 2c).
Figure 2 mRANTES and MIP-1b mRNA expression in non-inflamed and inflamed skins (a) Expression of mRANTES induced by different
doses of shikonin (50 or 100 μg/site/mice) in non-inflamed skin and statistic analysis data; (b) Time course of shikonin-induced
mRANTES mRNA expression in non-inflamed skin tissues. Shikonin was topically applied at 100 μg/site/mice. (c) Anti-inflammatory effect of
shikonin on the mRNA expression of mRANTES and MIP-1b in a TPA-induced inflamed skin model and statistic analysis data. The results are
representative of three independently performed experiments.
Figure 1 Induction of mRANTES expression by test phytochemicals in mouse skin tissues. Mouse skin was either untreated, or treated
with vehicle control solvent, gallic acid (GA), ferulic acid (FA), curcumin (CM), caffeic acid (CA), epigallocatechin gallate (EGCG) or shikonin (SK),
each at 0.7 mmole/site/mouse. TPA and hydrocortisone (H) were used as a positive and negative control, respectively. Skin samples were
collected at 24 h post treatment and mRANTES expression was determined by ELISA analysis. *, P< 0.05; ***, P <0.001, versus solvent treatment.
Error bars indicate SD.
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expression of mRANTES mRNA and protein in skin tissue
Next, expression levels of mRANTES from shikonin-
treated skin tissue were compared with that from
mRANTES cDNA vector-transfected skin tissue. The
mRNA expression of mRANTES was substantially
induced by shikonin at 12 hours post treatment, and the
expression was substantially increased at 24 hours post
treatment (Figure 3a). The mRNA expression level of
RANTES from empty vector-transfection was slightly
higher than that obtained with shikonin treatment.
Gene gun bombardment is known to mediate protein
expression of inflammatory cytokines, which has been
reported to result from an intrinsic response to physical
stress and tissue damage [8]. RANTES cDNA gene trans-
fection apparently increased the RANTES mRNA and pro-
tein expression levels, (Figure 3a and 3c, respectively), over
those from the vector only (i.e., tissue wounding only)
treated skin tissues. As compared to the “24 hours and
36 hours” -time period for shikonin-induced RANTES
expression, the gene gun-mediated transgenic expression
at both the mRNA and protein level can reach a substan-
tially higher level, and the expression time frame can last a
substantially longer period (Figure 3a and 3c).
Histological analysis of shikonin- and transgene-induced
RANTES protein expression in test skin tissue
Next we evaluated RANTES expression and regional tis-
sue damage in a time course experiment. To this end,
shikonin-treated or RANTES cDNA vector-transfected
skin tissues were collected at different time points and
subjected to immunohistochemistry assays. RANTES
protein expression was mainly detected in the epidermal
cell layers (Figure 4a). Vehicle-treated skin expressed lit-
tle or no RANTES protein. The shikonin induced
RANTES expression in the epidermis at 12 hours post
treatment gradually decreased between 24 hours and 36
hours post treatment. The pattern of empty DNA vector-
transfection resulted expression of RANTES is apparently
closely correlated with the physical stress and wound
healing activities observed for the bombarded skin tis-
s u e s ,a sw eh a v ep r e v i o u s l yr e p o r t e df o rg e n eg u n -
mediated transfection into skin tissue [20]. In contrast,
RANTES cDNA vector-transfection readily induced high
level RANTES expression from 12 hours; the expression
levels were maintained at 24 hours and were still elevated
at 36 hours post gene transfection. It is interesting to
note here that the expression of transgenic RANTES test
skin was mainly detected in the dermal layer of test skins
at 36 hours. This pattern may reflect the transcriptional
effects from RANTES transgene activity in skin. This in
situ RANTES expression pattern at the histological level
(Figure 4a) was distinguishable from the results obtained
from ELISA assays at total skin tissue level (Figure 3c).
A marked increase in level of TUNEL-positive apoptotic
cells was detected in gene gun-bombarded skin tissue
(pVector or pRANTES) at 12 and 24 hours, and was sub-
stantially reduced at 36 hours. When compared to gene
gun-bombardment, shikonin treatment induced relatively
fewer apoptotic cells in test skin tissue. Together, these
results suggest that topical treatment with shikonin may
induce mRANTES and increase accumulation of infil-
trated cells in test mouse skin tissues.
Shikonin pre-treatment increases the percentage of skin
DCs migration into draining lymph nodes after hgp100
cDNA vaccination
Next FITC sensitization assay was performed to trace the
trafficking of DCs, especially from the skin vaccination site
to draining lymph nodes. A significant increase in CD11c
+FITC
+MHC class II
+ cells was detected in lymph nodes
from mice bombarded with uncoated golden particles
(without any cDNA plasmid or the empty vector) when
compared to those from shikonin-treated mice (Figure. 5a,
b). This data suggests that particle/gene gun-generated
physical tissue injury/stress, but not shikonin treatment,
can effectively increase (approximately 2 fold) the migra-
tion of dendritic cells from skin to lymph nodes in vivo.
Therefore, we next tested whether topical “shikonin-
pretreatment” or “RANTES cDNA transgene-pretransfec-
tion” could contribute to an increase in trafficking of DCs
from the skin treatment site to the draining lymph nodes,
as we postulated that the physical stress resulting from the
gene gun treatment could help augment such activities.
Interestingly, a significantly higher frequency of CD11c
+FITC
+MHC class II
+ cells was detected in draining
lymph nodes of shikonin-pretreated mice (11.7%), even
higher than that in the RANTES transgene-pretransfected
mice (7.1%) (Figure 5c, d and 5e).
Effect of different immunization regimens on specific
cytotoxic T lymphocyte activity in test mice
In order to evaluate a possible adjuvantic effect of shi-
konin on gene gun-delivered hgp100 DNA cancer vac-
cine onto skin, we compared various different vaccine
regimes using combinations of hgp100 DNA vaccine
with pre-treatments with shikonin or RANTES cDNA
transgene vector in a B16/hgp100 melanoma model.
B16/hgp100 tumor-bearing mice were subjected to
three hgp100 vaccinations. Twenty-four hours prior to
each vaccination, topical application of shikonin or
transgenic delivery of RANTES cDNA via gene gun
was performed on the skin of test mice at the inocula-
tion site. Among all groups tested, the highest and
most potent CTL activities were detected in draining
lymph nodes of hgp100 cDNA-immunized mice that
were pre-treated with shikonin or pRANTES transgene
(Figure 6b, c).
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Page 5 of 12Figure 3 Comparison of mRANTES expression in skin subjected to topical treatment with shikonin, or gene transfection with
mRANTES cDNA expression vector. Mouse abdominal skin was treated with vehicle or shikonin (100 μg/site/mice), or transfected with an
empty vector (pVector) or mRANTES cDNA plasmid (pRANTES) via gene gun bombardment delivery. At the indicated time points, mRNA and
protein samples were extracted and expression of mRANTES was analyzed by RT-PCR and ELISA: (a) mRNA expression; (b) statistic data obtained
from (a); (c) protein expression.*P< 0.05, when compared with indicated vehicle treatment at 12 hours; #, P< 0.05, between indicated treatments.
Error bars indicate SD. The results are representative of three independently performed experiments.
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Topical and transdermal delivery of pharmacological
agents including vaccines is receiving increased research
attention due to recent expansion of the concept of skin
to a fascinating immune system. Our previous study
showed that a combination of transgenic expression of
RANTES and hgp100 as a chemotactic cancer vaccine can
elicit a much more efficient immune response than
hgp100 cDNA alone [20]. In this study, we first screened
several candidate phytochemicals for their possible induc-
tion of mRANTES expression in test skin tissue and found
that shikonin was able to induce the highest level of
mRANTES expression in mouse skin (Figure 1). Shikonin
has been shown to exhibit multiple and sometimes see-
mingly conflicting bio-activities, e.g., anti-tumor vs.
wound-healing effects [7,30] and anti-inflammation vs.
induction of pro-inflammatory chemokines [3]. A number
of studies have also reported that shikonin can exhibit
anti-tumor effects via inhibition of cell proliferation [31]
and proteasome activity [32], and by circumventing cancer
drug resistance via induction of necroptosis [7]. A herbal
medicine formulation made from Lithospermum erythror-
hizon containing shikonin has been shown to enhance
granuloma formation [30], and help reconstitution of skin
tissue [2] through induction of neovascularization in gran-
ulomatous tissue during wound-healing [4]. It is well-
known that shikonin confers a potent anti-inflammatory
effect, and we have previously shown that this effect on
skin may result from inhibition of the promoter activation
[8] and mRNA splicing [9] activities for TNFa expression.
As a follow up, we showed that shikonin can interfere
with or inhibit the maturation of DCs by suppressing
certain proinflammatory cytokines. Shikonin treatment
substantially affected transgenic and/or endogenous
Figure 4 RANTES expression and level of apoptosis in situ in shikonin and mRANTES cDNA transgene-treated skin tissues.
Immunohistochemistry was performed at the indicated time points from vehicle-treated, shikonin-treated, empty pVector-transfected or
pRANTES cDNA-transfected skin. (a) mRANTES protein expression; brownish staining (yellow arrows) was revealed by immunoperoxidase staining
using avidin-biotin-peroxidase complexes counterstained with hematoxylin. (b) In situ apoptosis detection showing apoptotic cells stained in
brownish color (black arrows) was observed in the epidermis. All test skin tissue sections were counterstained with hematoxylin. Similar results
were observed in skin biopsies from three different mice, and a representative histological result is shown. Scale bar: 200 μm.
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hgp100-immunized mice. (a) Scheme for testing DC migration from skin to lymph nodes (LNs). (b) Flow cytometry analysis of the the effects
of shikonin and transgenic RANTES on DC trafficking in skin. The data represent percentage of control FITC
+MHC class II
+ cells [in CD11c
+ DCs].
(c) Schema for pretreatment of skin with shikonin or transgenic RANTES and subsequent treatment with hgp100 cDNA vaccination. (d) Flow
cytometry analysis of DC-trafficking activities in test mice. Mouse abdominal immunization skin tissue sites were pre-treated with shikonin (100
μg/site/mouse) or transfected with RANTES cDNA 24 hours before immunization via gene gun bombardment for transgenic hgp100 expression.
(e) Flow cytometric analysis of skin DC trafficking activity shown in (d), data represent percentage of control FITC
+MHC class II
+ cells [in CD11c
+
DCs]. Error bars indicate SEM. (three mice per group).
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in mouse skin tissues in vivo [33] and in DCs or mono-
cytes ex-vivo [34]. In the present study we have shown
that under normal physiological conditions both shikonin
and curcumin, which have both been claimed to confer
various anti-inflammatory activities, were able to induce
expression of mRANTES which is generally considered to
be a pro-inflammatory chemokine. Secretion of RANTES
by keratinocytes is known to play a role in promoting
cutaneous wound-healing mediated via interaction with
the TWEAK/Fn14 signaling network [22,35]. This in situ
RANTES expression pattern at the histological level
(Figure 4a) was distinguishable from the results obtained
from ELISA assays at the total skin tissues extract level
(Figure 3c). Increasing evidences are showing that the
immune systems are highly sophisticated and can no
longer been dichotomized simply into “pro-inflammation”
versus “anti-inflammation” activities. There are overlap-
ping and parallel factors involved in the regulation of both
immune responses, as is known for the “multiple facets” of
IL-6 [36]. As for the different effects of shikonin under dif-
ferent physiological/pathological microenvironment,
together with our own and previous findings from others,
we can speculate some possibilities for elucidating these
observations. For example, after TPA treatments, several
responsive genes can be highly activated, including NFB,
RANTES, MIP-1b and TNFa. Shikonin has been shown
and considered as an anti-inflammatory phytochemical, as
we have reported previously [8,9]. Therefore, the inhibitory
effect of shikonin on TPA-induced RANTES and MIP-1b
gene expression may result into such anti-inflammatory
activity. On the other hand, in addition to inflammatory
signals, the expression of RANTES may be regulated by
other signals or factors, such as apoptotic signaling, FasL
[37] and calcineurin [38]. The present study indicates that
ah i g hd o s eo fs h i k o n i nm a ya c ta sas t r o n gs t i m u l u st ot h e
epidermis, which is made up largely of keratinocytes, and
induce a high level of RANTES expression, which may par-
tially result from transiently induced apoptotic activities in
the epidermis. In comparison with changes seen after gene
gun-bombardment of skin, only minor changes in the
levels of cell apoptosis in the epidermis and skin damage
were seen after shikonin treatment. Although a number of
skin vaccination approaches have been explored to boost
systemic immunity, new and optimized tissue manipulation
techniques for topical vaccination are still needed to
Figure 6 Specific cytotoxic T lymphcyte activities in test mice treated with different immunization regimes. (a) Schema for gene-based
vaccination and adjuvant treatment against test tumors in mouse model. One primer and two boosters were performed on days 0, 7 and 14.
Mouse immunization sites were either pre-treated with shikonin (100 μg/site/mice) or transfected with pRANTES vector 24 hours before each
primer and booster. The empty vector or vehicle control alone was used as a corresponding control. One week after the last booster, CTL
activities from splenocytes (b) and lymph node cells (c) were determined from immunized mice. Target tumor cells (B16/hgp100) were co-
cultured with effector cells at indicated ratios of effector:target (E:T) cells from 5:1 to 80:1 and assayed for CTL activity. *, P < 0.05, versus pVector
or vehicle controls. (Seven mice per group).
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ruption of epidermal structure. Within this paradigm, the
localized microenvironmental stress induced by shikonin
can be considered to be minor. In addition, shikonin treat-
ment did not induce a fast turnover of skin tissues. Overall,
the evidence presented here suggests that shikonin may
play a “multi-faceted” role in regulating certain activities
that induce a diversified repertoire of chemokines
expressed in skin, and some of these activities may corre-
late with the recruitment of DCs.
Several modalities of topical immunotherapy have been
developed [39]. A variety of adjuvants with potent
immuno-enhancing activities, such as toll-like receptor
ligands [40], have been employed for use in skin vaccina-
tion [40,41]. RANTES/CCL5 is characterized as a proin-
flammatory chemokine and can attract CCR5-expressing
immune cells, including immature DC and T cells. In our
previous study, although we showed that the CD11c
+ DCs
were significantly increased in mRANTES-transfected
s k i n ,w ew e r eu n a b l et oe x c l u de the possibility that the
CD11c
+ DCs which were increased in population as a
response to treatment with RANTES were immature. The
results of this study (Figure 4) and a previous report [19]
suggest that a gene gun-mediated DNA vaccine encoding
specific tumor-associated transgenes may provide a strong
stimulus, due to physical stress and/or a DNA backbone
signal which activates skin DCs, that enables DCs fully
mature and thus effectively migrate to the draining lymph
nodes where T-cell priming can take place. We further
suggest that topical application of shikonin can effectively
increase immature DC trafficking and accumulation at the
immunization site, thus facilitating the effectiveness of
subsequent vaccinations.
We further suggest that the induction of mRANTES by
shikonin can result in an accumulation of potent antigen
presenting cells, CD11
+DCs and presumably other respon-
sive immune cells such as NK cells, CD4
+ and CD8
+ T
cells, at the treatment target tissue site, which can in turn
increase the population of specific antigen presenting cells
that are exposed to test antigens by subsequent DNA-
based vaccination. An additional gene-based vaccination
may further contribute to the potency of the initial vaccine
by providing not only the tumor-associated antigenic
signals, but also providing a strong stimulus for the
maturation of skin DCs. The activated DCs carrying the
tumor-associated antigenic signals may then migrate to
the draining lymph nodes and elicit targeted innate and
adaptive immunities (Figure 7). An intriguing finding
obtained from this study is that shikonin, which has so
far mainly been recognized as a potent anti-inflammatory
agent, can also induce potent expression of the pro-
inflammatory chemokine mRANTES in un-inflamed or
un-stimulated skin tissues. The differential effects of shi-
konin on skin in different physiological environments may
result from an interaction between shikonin and different
participating or neighboring cells and/or the intrinsic che-
mical nature of shikonin which can modulate a specific
balance between the pro- and anti- inflammatory cyto-
kines and chemokines[42,43]. In this regard, our present
results showed that a specific immunization regime (i.e.,
shikonin pretreatment/hgp100 cDNA gene vaccination)
increased the population of migrated skin DCs in draining
lymph nodes (Figure 4) and augmented CTL activities
(Figure 6) in vaccinated mice. These results also show that
the anti-inflammatory activity of shikonin may only have a
minor restraining effect on the cellular events generated
by the subsequent vaccination.
Conclusion
In conclusion, our present study investigated the
mechanistic and multi-targeted molecular effect of shi-
konin on the trafficking of DCs, and we evaluated its
potential application as a DNA vaccine adjuvant. We
showed that shikonin, a phytochemical purified from
Lithospermum erythrorhizon, can induce the highest
level of expression of RANTES in normal skin tissues
among a number of anti-inflammatory phytochemicals
tested. In comparison with mouse RANTES cDNA gene
transfection, shikonin treatment induced a transient
high-level expression of mRANTES (up to 24 hours)
Figure 7 Proposed mechanism for mode of action of shikonin in skin tissues. Topical pretreatment with shikonin enhances the recruitment
of DCs and other responsive immune cells via induction of RANTES, and in turn, increases the trafficking and population of these immune cells
at a specific vaccination site. The increased number of immune cells accumulated at the vaccination site then increases the frequency of
exposure or transfection of cells after subsequent DNA-based vaccination. The gene-based vaccines can further provide strong stimuli, due to
the gene transfection process or the composition of the DNA vaccines (e.g., CpG), to activate skin DCs with transgenic antigenic signals to
migrate to the draining lymph nodes where naïve T cells may be primed.
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A human gp100 cDNA gene vaccination regimen in
combination with pretreatment with shikonin as an
adjuvant in a human gp100-transfected B16 mouse
tumor model significantly increased the cytotoxic T
lymphocyte activities on target tumor cells in spleno-
cytes and lymph node cells of the test mice. We believe
this shikonin treatment approach may be beneficial/pro-
mising for future clinical application to gene-based can-
cer vaccines. Future optimization of a DNA vaccination
schema and regimen may include the efforts to reduce
the undesirable effects of shikonin and amplify its bene-
ficial effect. Shikonin, as a natural phytochemical pro-
duct, warrants further evaluation as an adjuvant for
gene-based vaccines, especially for topical application
alongside vaccination or immunotherapy. The present
study may serve as a pilot approach or system for evalu-
ating the use of an immuno-stimulatory agent (e.g., shi-
konin) as an adjuvant for topical application on skin
alongside vaccines and gene delivery vectors.
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